About GD

This author has not yet filled in any details.
So far GD has created 15 blog entries.

Cernilton A® approved by KFDA in South Korea

2024-03-28T12:42:26+01:00February 2024|

Press release February 27, 2024. Cernilton A® approved by KFDA in South Korea AB Cernelle, in close and trusted partnership with DongKoo Bio&Pharma Co, Ltd, a leading Korean pharmaceutical company with focus in urology, allergy and dermatology, has been granted approval of Cernilton A® by the medical product agency KFDA in South Korea. Cernilton A®, is a herbal medicinal product for treatment of benign prostate diseases; Chronic Prostatitis and Benign Prostate Enlargement. Preparation for the market launch of Cernilton A®, has been initiated and the product is expected to be available for sale in May/June 2024. There is an [Read more]

Experimental in vivo model to evaluate the impact of Cernitin™ on pain response on induced chronic bladder inflammation

2023-11-29T23:20:57+01:00June 2022|

Céline Augé, Nishtman Dizeyi, Lena Ramnemark, Philippe Lluel, Magnus Grabe Objective: Inflammation of the urinary bladder may cause burdensome pain also called bladder pain syndrome (BPS). A limitation in understanding BPS pathophysiology is the lack of appropriate preclinical model. Previously published clinical and preclinical studies revealed positive impact of CernitinTM on pain relief in chronic prostatitis. The objective of this study was to evaluate the effects of CernitinTM on induced inflammation of the urinary bladder in rats. We also sought to identify biomarkers which might play a role in the management of BPS. READ MORE

Backahill enters into an agreement to sell AB Cernelle

2023-02-21T13:04:29+01:00November 2021|

Press release 16 November 2021. Backahill enters into an agreement to sell AB Cernelle. Backahill AB has entered into an agreement to sell all shares in the subsidiary AB Cernelle to the German pharmaceutical group Dermapharm AG. “We have had a long and very interesting time as owners of Cernelle, which has developed very positively under the management of CEO Ken Tinebo. In Dermapharm, Cernelle gets an owner who can continue to develop and support the company´s expansion, both geographically and product wise that it has strategically worked towards for a number of years now. The sale of Cernelle [Read more]

Cernelle enters China

2023-02-20T15:08:48+01:00September 2021|

Cernelle enters China. AB Cernelle, in partnership with MeiRui, a leading Chinese pharmaceutical company specialising in urology, has received approval for Shenitong®, which is an herbal medicinal product for the treatment of benign prostate diseases. Both companies are now preparing for the market launch of Shenitong®, with the product expected to be available on the Chinese market beginning of 2022. There are 700 million men in China aged between 15 and 64 years. Around 40 per cent, or 280 million men, are expected to experience symptoms associated with benign prostate conditions. Shenitong® (=Cernitol®Novum) is the only medicinal product that [Read more]

Impact of Cernitin TM on induced chronic prostatitis in animal model for understanding management of lower urinary tract symptoms

2023-08-28T12:05:20+02:00February 2021|

Sophie Chabot, Nishtman Dizeyi, Lena Ramnemark, Philippe Lluel, Per-Anders Abrahamsson, Magnus Grabe Background: Cernitin TM pollen extracts (brand name Cernilton®) alleviates symptoms related to common lower uro-genital tract disorders in men. The underlying mechanisms are ill-defined but the inflammatory pathway could be one of them. In a previous in vitro study it was shown that Cernitin TM induce a regulatory effect on inflammatory parameters. Methods: In this study, male Sprague Dawley rats were used to validate the effects of Cernitin TM in chronic prostatitis and benign prostatic hyperplasia. Pain was assessed by von Frey assay. READ MORE [Read more]

Cernelle – a 100% fossil-free company

2023-01-21T15:50:24+01:00May 2020|

Cernelle – a 100% fossil-free companyBiogas instead of natural gas, charging posts for cars, switching to LED lighting and detailed energy measurement. Following several years of concerted effort to reduce its environmental impact, pharmaceutical company Cernelle located outside of Ängelholm, Sweden, is now completely fossil free as regards its process and heating.AB Cernelle has recently signed an agreement with energy company Öresundskraft on delivery of biogas to replace natural gas in its production of herbal pharmaceutical products and to heat the facility’s premises.Other measures include the installation of charging posts for company cars and staff cars, a switch to LED [Read more]

COVID-19 and supply of medicines

2023-01-21T15:51:52+01:00March 2020|

COVID-19 and supply of medicines As the coronavirus outbreak continues to evolve globally, Cernelle is implementing the necessary precautions to safeguard the continued supply of our medicines and provide treatment for the people who need our help. Our supply chain remains intact, and we have not experienced any supply disruptions. The health and safety of employees at Cernelle is one of our top priorities, therefore we are following the recommendations from the government. Strict hygiene measures are taken to ensure safety at our sites. Delivering the required medicine to people living with prostate diseases while keeping our employees and [Read more]

Cernitol introduced to French urologists and pharmacists in Toulouse.

2023-02-20T15:33:47+01:00September 2019|

Cernitol introduced to French urologists and pharmacists in Toulouse. Cernitol 47 mg is now available for sale in France. During a scientific seminar held by Cernelle September 10th in Toulouse, Cernitol was introduced successfully to French urologists and pharmacists. The topic at this symposium was “inflammation in the prostate and chronic pelvic pain”, where by highly recognised urologists held interesting lectures with new data and views of these diseases. Introduction Pr. Pascal RISCHMANN Inflammation de la prostate: une pathologie fréquente Pr. Magnus GRABE Douleurs chroniques du plancher pelvien Pr. Xavier GAME Quel rôle a la phytothérapie dans [Read more]

Cernitol Novum is launched in France

2023-01-21T15:53:01+01:00August 2019|

Cernitol Novum is launched in France Cernitol Novum is now available in France under the brand name Cernitol 47 mg. Cernelle is expanding internationally by entering a large and promising market. The French have great confidence and long history of using herbal pharmaceuticals. Cernitol is the first drug approved using pollen extract, as a the active pharmaceutical ingredient, to effectively treat symptoms caused by benign prostate hyperplasia (BPH). It is estimated that 2 million men in France suffer from benign prostate diseases. Prevalence data shows that one out of two men between 55 and 70 years and eight out of [Read more]

The effects of Cernitin® on inflammatory parameters and benign prostatic hyperplasia: An in vitro study

2023-08-28T12:05:54+02:00June 2019|

Nishtman Dizeyi, Ingrid Yao Mattisson, Lena Ramnemark, Magnus Grabe4, Per‐Anders Abrahamsson The pollen extract Cernitin® is widely used for treatment of benign prostatic hyperplasia (BPH) and non‐bacterial chronin prostatitis. However, little is known about the underlying molecular mechanisms to explain the clinical effects of Cernitin®. In this study, we sought to investigate the cellular mechanisms by which Cernitin® induces its effects on human prostatic cell lines BPH‐1 and WPMY‐1 and primary human peripheral blood mononuclear cells (hPBMCs) in vitro. We examined the effects of Cernitin® formulas T60 and GBX on the protein expression, proliferation, and cytokines production. READ MORE [Read more]

Go to Top